Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBT (2016 - 2025)

Historic EBT for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$93.7 million.

  • Iovance Biotherapeutics' EBT fell 1010.69% to -$93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$398.3 million, marking a year-over-year increase of 428.03%. This contributed to the annual value of -$375.0 million for FY2024, which is 1620.3% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' EBT is -$93.7 million, which was down 1010.69% from -$109.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' EBT's 5-year high stood at -$77.0 million during Q4 2024, with a 5-year trough of -$118.1 million in Q4 2023.
  • Its 3-year average for EBT is -$104.0 million, with a median of -$107.4 million in 2023.
  • As far as peak fluctuations go, Iovance Biotherapeutics' EBT skyrocketed by 3482.11% in 2024, and later tumbled by 1127.35% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' EBT stood at -$118.1 million in 2023, then soared by 34.82% to -$77.0 million in 2024, then dropped by 21.63% to -$93.7 million in 2025.
  • Its EBT was -$93.7 million in Q3 2025, compared to -$109.7 million in Q2 2025 and -$118.0 million in Q1 2025.